Linax E 5/25 mg Tablet is a combination of two oral antihyperglycemic agents: Linagliptin, a DPP-4 inhibitor, and Empagliflozin, an SGLT2 inhibitor. This dual-action medication is designed to improve glycemic control in adults with type 2 diabetes mellitus.
Linagliptin: Enhances the levels of incretin hormones by inhibiting the DPP-4 enzyme, leading to increased insulin secretion and decreased glucagon release in a glucose-dependent manner.
Empagliflozin: Reduces renal glucose reabsorption by inhibiting the SGLT2 protein, resulting in increased urinary glucose excretion.